ClinicalTrials.gg
Not yet recruitingNCT06839339Updated Feb 21, 2025

Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD

A Phase 2 interventional study of AL-001 and Aflibercept in Wet Age-related Macular Degeneration (wAMD), sponsored by Beijing Anlong Biopharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Beijing Anlong Biopharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
60th of 91
40 · median 62
Started
2025
with 14 others
Phase 2
14 of 106
4 open now
Primary completion
2026-09
later than 20 of 42 live
Registered
85th of 106
by date
Lead sponsor
3 of 106
Beijing Anlong Biopharmaceutical Co., Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 60th largest by planned enrollment of the 91 interventional ones that give a count, is one of 15 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 20 of the 42 other live ones, and was the 85th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.

03

Conditions studied

  • Wet Age-related Macular Degeneration (wAMD)
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥ 50 and ≤ 85.
  2. The study eye was diagnosed with subfoveal active choroidal neovascularization (CNV) lesions secondary to wAMD.
  3. The study eye has response to anti-VEGF injections.
  4. The subject or their legal representative agrees to participate in this study and signs a written ICF.

Exclusion criteria

Exclusion Criteria:

  1. Non-wAMD induced CNV or macular edema in the study eye.
  2. Non-wAMD induced eye conditions that may affect central vision or medical history that may seriously affect central vision in the study eye.
  3. Uncontrolled glaucoma in the study eye.
  4. History of vitreoretinal surgery, antiglaucoma trabeculectomy, or other anti-glaucoma filtering surgery in the study eye.
  5. Refractive interstitial opacity that significantly affects visual function assessment or fundus examination in the study eye.
  6. Ametropia (high myopia or high hyperopia) > 8.0D in the study eye, or significant posterior scleral staphyloma in the study eye.
  7. Malignant tumor in any eye, including but not limited to eye lymphoma or choroidal melanoma.
  8. None of intraocular inflammation in the study eye.
  9. Other conditions that may affect compliance or may not be suitable to participate in this trial in the opinion of investigator.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    AL-001 Dose 1

    Injection of dose 1

    Drug: AL-001

  • Experimental
    AL-001 Dose 2

    Injection of dose 2

    Drug: AL-001

  • Active comparator
    Aflibercept

    Intravitreal injection

    Drug: Aflibercept

Interventions

  • DrugAL-001

    Administered via suprachoroidal space injection.

  • Intravitreal injection

06

What researchers measure

Primary outcomes

  1. Evaluate the effect of AL-001 on BCVA

    Change in BCVA

    Time frame: Week 24

Secondary outcomes

  1. Safety

    Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Week 56

  2. Evaluate the effect of AL-001 on central retinal thickness (CRT)

    Mean change from baseline in CRT as measured

    Time frame: Week 56

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Sep 2026, 19 months later.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 19 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Feb 21, 2025
StartEst.
Feb 18, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Jan 30, 2027
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06839339
Lead sponsor
Beijing Anlong Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Feb 18, 2025 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Feb 21, 2025

Study contacts

Anlong Bio
Contact
info@anlongbio.com
+86-010-80414166

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion